AIMS: To determine whether testing for isolated 1p or 19q losses, or as a codeletion, has any significance in the workup of glioblastomas (GBMs). METHODS: Upfront 1p/19q testing by fluorescence in situ hybridization (FISH) and/or polymerase chain reaction (PCR)-based loss of heterozygosity (LOH) was done in 491 gliomas that were histologically diagnosed as GBMs. Outcomes were determined and measured against 1p/19q results. RESULTS: Twenty-eight showed apparent 1p/19q codeletion by either FISH and/or PCR-based LOH, but only 1/26 showed codeletion by both tests. Over 90% of tumours with apparent codeletion by either FISH or LOH also had 10q LOH and/or EGFR amplification, features inversely related to true whole-arm 1p/19q codeletion. Furthermore, only 1/28 tumours demonstrated an R132H IDH1 mutation. Neither 1p/19q codeletion by FISH nor LOH had an impact on GBM survival. Isolated losses of 1p or 19q also had no impact on survival. CONCLUSIONS: These data suggest that (i) 1p/19q testing is not useful on gliomas that are histologically GBMs; (ii) codeletion testing should be reserved only for cases with compatible morphology; and (iii) EGFR, 10q, and IDH1 testing can help act as safeguards against a false-positive 1p/19q result.
AIMS: To determine whether testing for isolated 1p or 19q losses, or as a codeletion, has any significance in the workup of glioblastomas (GBMs). METHODS: Upfront 1p/19q testing by fluorescence in situ hybridization (FISH) and/or polymerase chain reaction (PCR)-based loss of heterozygosity (LOH) was done in 491 gliomas that were histologically diagnosed as GBMs. Outcomes were determined and measured against 1p/19q results. RESULTS: Twenty-eight showed apparent 1p/19q codeletion by either FISH and/or PCR-based LOH, but only 1/26 showed codeletion by both tests. Over 90% of tumours with apparent codeletion by either FISH or LOH also had 10q LOH and/or EGFR amplification, features inversely related to true whole-arm 1p/19q codeletion. Furthermore, only 1/28 tumours demonstrated an R132HIDH1 mutation. Neither 1p/19q codeletion by FISH nor LOH had an impact on GBM survival. Isolated losses of 1p or 19q also had no impact on survival. CONCLUSIONS: These data suggest that (i) 1p/19q testing is not useful on gliomas that are histologically GBMs; (ii) codeletion testing should be reserved only for cases with compatible morphology; and (iii) EGFR, 10q, and IDH1 testing can help act as safeguards against a false-positive 1p/19q result.
Authors: Christine E Fuller; Robert E Schmidt; Kevin A Roth; Peter C Burger; Bernd W Scheithauer; Ruma Banerjee; Kathryn Trinkaus; Richard Lytle; Arie Perry Journal: J Neuropathol Exp Neurol Date: 2003-11 Impact factor: 3.685
Authors: Gaspar Kitange; Anjan Misra; Mark Law; Sandra Passe; Thomas M Kollmeyer; Matthew Maurer; Karla Ballman; Burt G Feuerstein; Robert B Jenkins Journal: Genes Chromosomes Cancer Date: 2005-01 Impact factor: 5.006
Authors: Daniel J Brat; Wendy F Seiferheld; Arie Perry; Elizabeth H Hammond; Kevin J Murray; Alan R Schulsinger; Minesh P Mehta; Walter J Curran Journal: Neuro Oncol Date: 2004-04 Impact factor: 12.300
Authors: Kenneth B Fallon; Cheryl A Palmer; Kevin A Roth; L Burton Nabors; Wenquan Wang; Mark Carpenter; Ruma Banerjee; Peter Forsyth; Keith Rich; Arie Perry Journal: J Neuropathol Exp Neurol Date: 2004-04 Impact factor: 3.685
Authors: Maryam Fouladi; Kathleen Helton; James Dalton; Elizabeth Gilger; Amar Gajjar; Thomas Merchant; Larry Kun; Irene Newsham; Peter Burger; Christine Fuller Journal: Cancer Date: 2003-11-15 Impact factor: 6.860
Authors: J A Kraus; J Koopmann; P Kaskel; D Maintz; S Brandner; J Schramm; D N Louis; O D Wiestler; A von Deimling Journal: J Neuropathol Exp Neurol Date: 1995-01 Impact factor: 3.685
Authors: J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis Journal: J Natl Cancer Inst Date: 1998-10-07 Impact factor: 13.506
Authors: Kevin Shee; Meagan Chambers; Edward G Hughes; Damian A Almiron; Sophie J Deharvengt; Donald Green; Joel A Lefferts; Angeline S Andrew; William F Hickey; Gregory J Tsongalis Journal: J Neurooncol Date: 2020-06-24 Impact factor: 4.130
Authors: Dayane B Koshiyama; Patrícia Trevisan; Carla Graziadio; Rafael F M Rosa; Bibiana Cunegatto; Juliete Scholl; Valentina O Provenzi; Alexandre P de Sá; Fabiano P Soares; Maíra C Velho; Nelson de A P Filho; Ceres A Oliveira; Paulo R G Zen Journal: J Neurooncol Date: 2017-08-30 Impact factor: 4.130
Authors: Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-22 Impact factor: 4.254